COVID-19 impact: MG Motor India sees retail sales of 710 units in May

The company has resumed production at its Halol manufacturing plant with approximately 30 percent capacity utilisation, MG Motor India said in a statement.

PTI

June 01, 2020 / 11:51 IST

MG Motor India on Monday reported retail sales of 710 units in May amidst supply chain constraints of coronavirus-induced lockdown.

The company has resumed production at its Halol manufacturing plant with approximately 30 percent capacity utilisation, MG Motor India said in a statement.

About 65 percent of its showrooms and service stations across the country are also operational with reduced manpower, it added.

Commenting on business resumption and sales performance, MG Motor India Director Sales Rakesh Sidana said, "supply chain disruption coupled with stricter credit financing along with non-operation of some dealerships due to the lockdown have impacted our sales in May."

He further said, "the production loss notwithstanding, our front-end retail operations continue to operate with less-than-normal staff strength. At these times, we remain connected with our customers waiting for delivery of the HECTOR and continue to prioritise deliveries with supply chain improvements in June."

COVID-19 Vaccine

Frequently Asked Questions

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

Show